The lead program, VMT-α-NET, continues to show a favorable tolerability profile with durable disease control in neuroendocrine tumors. The study is on track to achieve nearly one year of follow-up for all 46 patients in Cohort 2 by mid-2026. The company also highlighted that data across all dose levels in the VMT-α-NET program provide development optionality and support for a robust clinical evidence package for future regulatory engagement.
In terms of operational execution, the company plans to submit clinical updates for all three clinical programs at medical conferences throughout 2026. The financial summary revealed a net loss of $103.1 million for the year ended December 31, 2025, compared to a net loss of $79.3 million in 2024. The increase in losses was attributed to heightened research and development expenses, which rose to $84.2 million, primarily due to increased clinical site activities and personnel costs.
Overall, while the financial results indicate a challenging year, the company’s strategic outlook remains positive, with significant cash reserves and ongoing clinical trials that could lead to future growth and development opportunities.
